Other news
![RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013](https://ucarecdn.com/42251bd5-d9e6-4107-bbd7-ac13f0c8609a/-/smart_resize/250x170/-/format/preserve/-/quality/lighter/-/strip_meta/none/citryll-cityview-combined-logo.png){kind=logo}
RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013
Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Interested in a collaboration?
Contact us to discuss the possibilities.